Skip to Content
Morningstar

AstraZeneca PLC AZN

Morningstar Rating
Unlock
Stock XLON Rating as of
GBX 12,600.00 +44.00 (0.35%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

AstraZeneca: Investor Day Reveals Optimistic 2030 Sales Guidance, but Pipeline Holds Possible Upside

Damien Conover

We are holding steady to our AstraZeneca fair value estimate following an investor day, which highlighted 2030 sales guidance of $80 billion and 2026 core operating margins of mid-30s. While we believe the operating margin expansion by 2026 is likely, we remain skeptical regarding the 2030 sales guidance, which is almost 30% above our estimate and consensus. If Astra can achieve this long-term sales goal, then there is upside to our fair value estimate.

Read Full Report

Price vs Fair Value

View History
AZN is trading within a range we consider fairly valued.
Price
GBX 12,556.00
Fair Value
GBX 53,488.00
Uncertainty
Medium
1-Star Price
GBX 97,673.00
5-Star Price
GBX 3,569.00
Economic Moat
Lvsd
Capital Allocation
Bmkfrmbkd

Bulls Say, Bears Say

Bulls

The company is expanding its oncology presence with several important pipeline products. In particular, the company's EGFR drug Tagrisso looks well positioned to drive major cashflows over the next decade.

Bears

The company's strong entrenchment in respiratory disease could cause challenges, as pricing power in this market tends to be weak.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AZN is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
GBX 12,556.00
Day Range
GBX 12,480.00–12,632.00
52-Week Range
GBX 9,461.00–12,704.00
Bid/Ask
GBX 12,304.00 / GBX 12,650.00
Market Cap
GBX 19.53 Tril
Volume/Avg
1.6 Mil / 2.4 Mil

Key Statistics

Price/Earnings (Normalized)
21.35
Price/Sales
5.18
Dividend Yield (Trailing)
1.81%
Dividend Yield (Forward)
1.81%
Total Yield
1.81%

Company Profile

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Growth
Total Number of Employees
89,900
Website
https://www.astrazeneca.com

Competitors

Valuation

View More
Metric
AZN
LLY
MRK
Price/Earnings (Normalized)
 21.3590.9060.21
Price/Book Value
 6.5663.058.20
Price/Sales
 5.1821.375.42
Price/Cash Flow
 24.4188.8219.06
Price/Earnings
AZN
LLY
MRK

Financial Strength

Metric
AZN
LLY
MRK
Quick Ratio
 0.700.680.68
Current Ratio
 0.891.351.25
Interest Coverage
 5.3214.113.97
Quick Ratio
AZN
LLY
MRK

Profitability

Metric
AZN
LLY
MRK
Return on Assets (Normalized)
 59.78%11.20%5.22%
Return on Equity (Normalized)
 157.53%57.69%13.56%
Return on Invested Capital (Normalized)
 88.21%20.65%8.29%
Return on Assets
AZN
LLY
MRK
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - General Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
BwqnrwyjPff$807.8 Bil
 Johnson & Johnson
JNJ
VzjykqngClzh$354.0 Bil
 Merck & Co Inc
MRK
JcckntbfFvqs$331.0 Bil
 AbbVie Inc
ABBV
HwzzqwtKddj$299.2 Bil
 AstraZeneca PLC ADR
AZN
BwkjtltmxKhlcp$249.0 Bil
 Roche Holding AG ADR
RHHBY
ChzpwwrqpFmk$220.5 Bil
 Novartis AG ADR
NVS
HplgljvShwj$217.7 Bil
 Amgen Inc
AMGN
PbbjvxclTbfz$163.6 Bil
 Pfizer Inc
PFE
WljtqwcGkrg$162.0 Bil
 Sanofi SA ADR
SNY
WxycprcfKhjz$124.0 Bil

Sponsor Center